Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NYSE:JNJ NYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$220.04-0.3%$201.98$163.81▼$221.85$388.71B0.536.42 million shs1.05 million shsJNJJohnson & Johnson$175.44-1.0%$172.09$140.68▼$181.16$422.51B0.48.83 million shs1.77 million shsMRKMerck & Co., Inc.$81.06-0.1%$82.88$73.31▼$119.20$202.46B0.3714.96 million shs1.80 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+1.80%+3.93%+6.75%+18.84%+13.78%JNJJohnson & Johnson+0.28%+0.73%+0.41%+17.38%+5.93%MRKMerck & Co., Inc.+0.05%-3.51%-3.68%+2.33%-31.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$220.04-0.3%$201.98$163.81▼$221.85$388.71B0.536.42 million shs1.05 million shsJNJJohnson & Johnson$175.44-1.0%$172.09$140.68▼$181.16$422.51B0.48.83 million shs1.77 million shsMRKMerck & Co., Inc.$81.06-0.1%$82.88$73.31▼$119.20$202.46B0.3714.96 million shs1.80 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+1.80%+3.93%+6.75%+18.84%+13.78%JNJJohnson & Johnson+0.28%+0.73%+0.41%+17.38%+5.93%MRKMerck & Co., Inc.+0.05%-3.51%-3.68%+2.33%-31.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.93Moderate Buy$222.681.20% UpsideJNJJohnson & Johnson 2.62Moderate Buy$177.871.38% UpsideMRKMerck & Co., Inc. 2.33Hold$106.4131.28% UpsideCurrent Analyst Ratings BreakdownLatest MRK, JNJ, and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/17/2025ABBVAbbVieBerenberg BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$170.00 ➝ $270.009/17/2025MRKMerck & Co., Inc.Berenberg BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$100.00 ➝ $90.009/16/2025ABBVAbbVieJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$200.00 ➝ $235.009/16/2025JNJJohnson & JohnsonJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$185.00 ➝ $200.009/15/2025ABBVAbbVieCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$215.00 ➝ $245.009/12/2025ABBVAbbVieWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$240.00 ➝ $260.009/12/2025ABBVAbbVieBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$215.00 ➝ $240.008/25/2025ABBVAbbVieRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/21/2025JNJJohnson & JohnsonCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$185.00 ➝ $200.008/12/2025ABBVAbbViePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$231.008/11/2025ABBVAbbViePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$58.33B6.66$15.20 per share14.48$1.90 per share115.81JNJJohnson & Johnson$90.63B4.66$13.04 per share13.45$29.69 per share5.91MRKMerck & Co., Inc.$64.17B3.16$9.46 per share8.57$18.33 per share4.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.10104.7815.741.396.45%699.66%13.64%10/29/2025 (Estimated)JNJJohnson & Johnson$14.07B$9.3518.7615.852.2525.00%32.49%13.00%10/14/2025 (Estimated)MRKMerck & Co., Inc.$17.12B$6.4912.498.190.8325.79%41.05%16.55%10/30/2025 (Estimated)Latest MRK, JNJ, and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/14/2025Q3 2025JNJJohnson & Johnson$2.78N/AN/AN/A$23.73 billionN/A7/31/2025Q2 2025ABBVAbbVie$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billion7/29/2025Q2 2025MRKMerck & Co., Inc.$2.03$2.13+$0.10$1.76$15.92 billion$15.81 billion7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.562.98%N/A312.38%53 YearsJNJJohnson & Johnson$5.202.94%N/A55.61%64 YearsMRKMerck & Co., Inc.$3.243.99%N/A49.92%14 YearsLatest MRK, JNJ, and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/5/2025ABBVAbbViequarterly$1.643.08%10/15/202510/15/202511/14/20257/22/2025MRKMerck & Co., Inc.quarterly$0.814%9/15/20259/15/202510/7/20257/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/20256/20/2025ABBVAbbViequarterly$1.643.54%7/15/20257/15/20258/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.740.61JNJJohnson & Johnson0.501.010.76MRKMerck & Co., Inc.0.691.421.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%JNJJohnson & Johnson69.55%MRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%JNJJohnson & Johnson0.16%MRKMerck & Co., Inc.0.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.76 billionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableMRKMerck & Co., Inc.75,0002.50 billion2.49 billionOptionableMRK, JNJ, and ABBV HeadlinesRecent News About These CompaniesRate Cuts Could Actually Spark a Sell-Off: 5 Safe JP Morgan Dividend Stocks2 hours ago | 247wallst.comMerck & Co., Inc. $MRK Shares Sold by Fulton Bank N.A.4 hours ago | marketbeat.comNorthCrest Asset Manangement LLC Increases Stock Position in Merck & Co., Inc. $MRK4 hours ago | marketbeat.comCypress Point Wealth Management LLC Acquires New Holdings in Merck & Co., Inc. $MRK5 hours ago | marketbeat.comWealth Enhancement Advisory Services LLC Has $134.57 Million Stock Holdings in Merck & Co., Inc. $MRK5 hours ago | marketbeat.comStrathmore Capital Advisors Inc. Takes $488,000 Position in Merck & Co., Inc. $MRK5 hours ago | marketbeat.comRadnor Capital Management LLC Acquires 15,210 Shares of Merck & Co., Inc. $MRK5 hours ago | marketbeat.comCentral Valley Advisors LLC Has $1.83 Million Holdings in Merck & Co., Inc. $MRK5 hours ago | marketbeat.comMn Services Vermogensbeheer B.V. Purchases 7,500 Shares of Merck & Co., Inc. $MRK5 hours ago | marketbeat.comSunpointe LLC Acquires 3,575 Shares of Merck & Co., Inc. $MRK5 hours ago | marketbeat.comSwedbank AB Sells 113,211 Shares of Merck & Co., Inc. $MRK5 hours ago | marketbeat.comSecure Asset Management LLC Cuts Stake in Merck & Co., Inc. $MRKSeptember 18 at 6:03 AM | marketbeat.comProcyon Advisors LLC Has $1.78 Million Stake in Merck & Co., Inc. $MRKSeptember 18 at 6:02 AM | marketbeat.comMerck & Co., Inc. $MRK Stock Holdings Trimmed by Pallas Capital Advisors LLCSeptember 18 at 6:01 AM | marketbeat.comSumitomo Mitsui DS Asset Management Company Ltd Purchases 26,413 Shares of Merck & Co., Inc. $MRKSeptember 18 at 5:52 AM | marketbeat.comGateway Investment Advisers LLC Has $42.24 Million Stock Holdings in Merck & Co., Inc. $MRKSeptember 18 at 5:44 AM | marketbeat.comSivia Capital Partners LLC Increases Position in Merck & Co., Inc. $MRKSeptember 18 at 4:56 AM | marketbeat.comMerck & Co., Inc. $MRK Shares Sold by Dynamic Advisor Solutions LLCSeptember 18 at 4:56 AM | marketbeat.comSarasin & Partners LLP Grows Stock Holdings in Merck & Co., Inc. $MRKSeptember 18 at 4:56 AM | marketbeat.comMerck & Co., Inc. $MRK Shares Sold by Eldred Rock Partners LLCSeptember 18 at 4:55 AM | marketbeat.comLineweaver Wealth Advisors LLC Has $2.12 Million Holdings in Merck & Co., Inc. $MRKSeptember 18 at 4:55 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 20253 Dividend Stocks to Hold Through Market Volatility This FallBy Chris Markoch | September 16, 2025MRK, JNJ, and ABBV Company DescriptionsAbbVie NYSE:ABBV$220.04 -0.77 (-0.35%) As of 11:13 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Johnson & Johnson NYSE:JNJ$175.44 -1.76 (-0.99%) As of 11:13 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Merck & Co., Inc. NYSE:MRK$81.06 -0.09 (-0.10%) As of 11:13 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Is Netflix's Ad Deal With Amazon the Catalyst for a New Uptrend? DoorDash Buys Deliveroo: A Game Changer? The Side of Rate Cuts Nobody Is Telling You About Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
